How Knowles’ Custom Pulse Power Capacitor Push Could Reframe the Medtech Story for KN Investors

• Earlier this week, Knowles announced an expansion of its high‑performance capacitor portfolio for pulse power applications, highlighting custom film and ceramic solutions that support tightly controlled energy discharges across medical, industrial, scientific, and energy research uses.
• This push into advanced, application‑specific pulse power capacitors underscores how Knowles aims to deepen its role in critical systems such as neuromodulation therapies, semiconductor CO₂ lasers, downhole perforation tools, defibrillators, and plasma science research platforms.
• Next, we’ll examine how this expansion into customized pulse power capacitors could influence Knowles’ investment narrative around medtech and industrial growth.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Knowles Investment Narrative Recap

To own Knowles, you need to believe its specialty components can keep earning premium pricing in medtech, industrial, and defense while margins hold up despite factory and product mix pressures. The new pulse power capacitor expansion supports that thesis around custom, higher value parts, but it does not obviously change the near term margin risk tied to ramp inefficiencies and higher scrap that investors are already watching closely.

Among recent announcements, the ongoing share repurchase program stands out next to this capacitor news. Knowles has bought back nearly 15 million shares since 2020 and raised the authorization to US$400,000,000, which ties into the core catalyst of turning improving earnings and cash flow into per share value creation while newer product lines like inductors and specialty film scale up.

Yet even as custom capacitors expand Knowles’ opportunity set, the risk that persistent factory inefficiencies could keep eroding margins is something investors should be aware of...

Read the full narrative on Knowles (it's free!)

Knowles’ narrative projects $741.0 million in revenue and $120.2 million in earnings by 2029.

Uncover how Knowles' forecasts yield a $36.25 fair value, a 12% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$762,000,000 and earnings about US$135,000,000 by 2029, so if you are weighing that view against concerns about customer concentration and the new pulse power push, this week’s news may eventually shift how you think about both the upside and the risks.

Explore 2 other fair value estimates on Knowles - why the stock might be worth 12% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Knowles research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Knowles research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Knowles' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com